



September 30, 2025

PROVIDER ALERT
MedStar Family Choice Maryland

The MedStar Family Choice made the decision **to prefer biosimilars for the products listed in table below** in the medical drug formulary **effective November 1, 2025**, and **requires prior authorization**.

Chemical Name (Drug Class)	HCPCS	Preferred Products	Non-Preferred Products
Aflibercept (VEGF Inhibitor)	Q5147	Pavblu	Eylea
Bevacizumab (VEGF Inhibitor)	Q5118	Zirabev	Avastin Mvasi Vegzelma
Infliximab (TNF inhibitor)	Q5121	Avsola	Remicade Renflexis Inflectra
Pegfilgrastim (Hematopoietic agent)	Q5108	Fulphila	Neulasta Fylmetra Nyvepria Stimufend Udenyca
Ranibizumab (VEGF Inhibitor)	Q5128	Cimerli	Lucentis Byooviz
Rituximab (Anti-CD20 monoclonal antibody)	Q5123 Q5119	Riabni Ruxience	Rituxan Truxima
Tocilizumab (IL-6 antagonist)	Q5135	Tyenne	Actemra Tofidence
Trastuzumab (HER2 receptor antagonist)	Q5114 Q5113	Ogivri Herzuma	Herceptin Kanjinti Ontruzant Trazimera
Denosumab (RANKL inhibitor)	Q5136 Q5157	Jubbonti/Wyost Stoboclo/Osenvelt	Prolia/Xgeva

**It's how we
treat people.**



MedStar Family Choice

Chemical Name (Drug Class)	HCPCS	Preferred Products	Non-Preferred Products
Ustekinumab (IL-23 inhibitor)	Q5100 Q5099	Yesintek Steqeyma	Stelara Otulfi Selarsdi Wezlana Pyzchiva

MedStar Family Choice will continue to cover any existing non-preferred medical drug services that were already approved prior to November 1, 2025.

If you have any questions, please call 410-933-2200.

Respectfully,

Damien Doyle MD
Senior Medical Director of MedStar Family Choice-Maryland

**It's how we
treat people.**